Cannabis News for Florda
 Cansortium Inc. (CSE: TIUM.U) (OTCQX: CNTMF) (“Cansortium” or the “Company”), a vertically-integrated cannabis company operating under the Fluent™ brand, today announced financial results for the... CANSORTIUM REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS

 Cansortium Inc. (CSE: TIUM.U) (OTCQX: CNTMF) (“Cansortium” or the “Company”), a vertically-integrated cannabis company operating under the Fluent™ brand, today announced financial results for the second quarter ended June 30, 2021, as well as recent operational highlights. Unless otherwise indicated, all results are presented in U.S. dollars.

Cansortium Inc logo (CNW Group/Cansortium Inc)

“We continued to drive growth and profitability in our key markets during the second quarter, as reflected by another month of record sales in May,” said CEO Robert Beasley. “Our continued focus on providing differentiated, high-quality flower and wellness products has been well received by our patients. Additionally, we are now offering several boutique strains that have never been sold in the Florida market.”

Cansortium significantly improved its balance sheet during the quarter with debt and equity financings of nearly $90 million, which enabled the Company to cancel legacy debt and extend maturities to 2025, as well as redeem all outstanding convertible notes. Cansortium now has both the capital and flexibility needed to execute its expansion plans.

Mr. Beasley continued, “Our core operations in Florida are performing well and our expansion plans are fully-funded. There have been minor supply chain and construction delays for several projects in Florida, which will delay the expected timing of our production ramp and push our schedule back by approximately two months. In addition, we have experienced delays in the Michigan market which, albeit a small market for us, will also impact our guidance for 2021 as we continue to hold product for sale to hedge against volatile pricing.

“Overall, we continue to expect significant growth in 2021.  Our revised outlook for 2021 calls for $70-80 million of revenue with $18-26 million of adjusted EBITDA1, reflecting year-over-year growth of approximately 43% and 114%, respectively. We see upside to these numbers if the construction market opens up earlier than our current projections.

1 Adjusted EBITDA is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates adjusted EBITDA from EBITDA plus (minus) unrealized loss (gain) on embedded derivatives, plus (minus) certain one-time non-operating expenses, as determined by management. A reconciliation from adjusted EBITDA to net loss is included in the accompanying financial schedules.

“Other progress on various initiatives includes last week’s opening of a new dispensary in Mechanicsburg, Pennsylvania, and securing our third Pennsylvania location in Annville, which we expect to open by the end of the year. In addition, we expect to open our 27th dispensary in Florida by the end of the third quarter and have identified four additional sites for continued growth in the first half of 2022.”

Q2 2021 Financial Highlights (vs. Q2 2020)

  • Revenue increased 24% to $16.5 million compared to $13.2 million.
  • Florida revenue increased 22% to $14.6 million compared to $12.0 million.
  • Adjusted gross profit2 increased 24% to $10.7 million or 65.1% of revenue, compared to $8.7 million or 65.5% of revenue.
  • Adjusted EBITDA approximately doubled to $5.2 million or 31.8% of revenue, compared to $2.6 million or 19.7% of revenue.
  • At June 30, 2021, the Company had approximately $26 million of cash and cash equivalents and $71 million of total debt, with approximately 264 million fully diluted shares outstanding (based on treasury stock method and share price on June 30, 2021).

Recent Operational Highlights

  • Launched Sweetwater, a new line of premium cannabis whole flower.
  • Hired a new Head of Cultivation.
  • Appointed multiple new board members, including Mark Eckenrode, Alex Spiro, and the Company’s new Executive Chairman of the Board, William Smith.
  • In July, the Company opened its 26th Florida dispensary in Deerfield Beach.
  • All convertible notes from the Company’s capital structure were converted to shares during the second quarter. A total of approximately $18.0 million of debt was converted into common shares of the Company.
  • The Company sold approximately 2,600 lbs. of biomass from Michigan inventory in July.
Adjusted gross profit is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates adjusted gross profit from gross profit plus (minus) the changes in fair value of biological assets, as presented in the consolidated statement of operations.

2021 Outlook
The Company is revising its 2021 outlook for revenue to range between $70-$80 million, with adjusted EBITDA ranging between $18-$26 million. This compares to approximately $52 million of revenue and $10 million of adjusted EBITDA in 2020.

In Florida, Cansortium continues to expect a total of 27 dispensaries to be operational by the end of 2021 and has identified four additional locations to be opened in 2022. In Michigan, the Company is holding 900 lbs. of flower prepared for sale. However, due to the pricing volatility, the Company is timing the sales cycle to realize optimal value.

The Company’s unaudited consolidated financial statements and accompanying notes, along with the Management Discussion and Analysis (MD&A), will be available under the Company’s profile on SEDAR at and are also accessible through the Investor Relations section of the Company’s website at

Conference Call
The Company will host a conference call and live audio webcast tomorrow at 8:30 a.m. Eastern time to discuss its financial results and operational highlights.

Toll-free dial-in number: (800) 319-4610
International dial-in number: (604) 638-5340
Conference ID: 10016120
Link: Cansortium Q2 2021 Earnings Call

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Elevate IR at (949) 200-4603.

The conference call will also be available for replay via the News & Events section of the Company’s investor relations website at

About Cansortium Inc.
Cansortium is a vertically-integrated cannabis company with licenses and operations in Florida, Pennsylvania, Michigan and Texas. The Company operates under the Fluent™ brand and is dedicated to being one of the highest quality cannabis companies for the communities it serves. This is driven by Cansortium’s unrelenting commitment to operational excellence in cultivation, production, distribution and retail. The Company is headquartered in Miami, Florida.

Cansortium Inc.’s common shares trade on the CSE under the symbol “TIUM.U” and on the OTCQX Best Market under the symbol “CNTMF.” For more information about the Company, please visit

Forward-Looking Information
Certain information in this news release may constitute forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates, and projections regarding future events.

Forward-looking information is necessarily based on many opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For further information:

(USD ‘000)
June 30,
December 31,
Current assets
Cash and cash equivalents$26,004$3,392
Accounts receivable122148
Inventory, net5,5605,006
Biological assets2,4951,914
Note receivable4,4623,859
Prepaid income taxes1,598
Prepaid expenses and other current assets1,2671,365
Total current assets41,50815,684
Investment held for sale200200
Property and equipment, net25,30919,517
Intangible assets, net96,26997,035
Right-of-use assets19,00819,094
Other assets486425
Total assets$187,033$154,531
Current liabilities
Accounts payable4,5304,808
Accrued liabilities6,8347,614
Income taxes payable8,925
Derivative liabilities7,412
Current portion of notes payable37538,583
Lease obligations2,1811,894
Total current liabilities13,92069,236
Notes payable, net of current portion and loan issuance costs53,41013,182
Lease obligations, net of current portion20,88920,811
Deferred income taxes24,43023,471
Total liabilities112,649126,700
Shareholders’ equity
Share capital196,588137,835
Share-based compensation reserve5,7174,675
Equity conversion feature11,04411,044
Accumulated deficit(168,723)(138,609)
Accumulated other comprehensive loss(390)(379)
Total shareholders’ equity 74,38427,831
Total liabilities and shareholders’ equity$187,033$154,531
USD (‘000)
 For the three months
ended June 30, 
 For the six months
ended June 30, 
Revenue, net of discounts$16,469$13,241$31,584$23,404
Cost of goods sold5,7454,56711,1528,227
Gross profit before fair value adjustments10,7248,67420,43215,177
Realized fair value of increments on inventory sold(4,727)(4,953)(9,320)(12,515)
Unrealized change in fair value of biological assets(1,224)7,5725,65519,682
Gross profit4,77311,29316,76722,344
General and administrative2,8683,0646,1566,202
Share-based compensation2852,3623,5173,249
Sales and marketing3,5153,4817,0616,602
Depreciation and amortization1,5471,5723,0783,074
Total expenses8,21510,47919,81219,127
Loss from operations(3,442)814(3,045)3,217
Other expense (income)
Interest expense, net4,7193,7987,8497,557
Change in fair market value of derivative liability(1,143)(828)(1,551)1,007
Loss on debt settlement10,75110,751
Private placement issuance expense6,6406,640
Equity loss on investment in associate31215
Loss on debt restructuring8,065
(Gain)/Loss on disposal of assets1(54)50(54)
Other (income) expense (18)(8)(131)7
Total other expense (income)20,9502,93923,60916,797
Loss before income taxes(24,392)(2,125)(26,654)(13,580)
Income taxes5943,3083,4316,141
Net loss(24,986)(5,433)(30,085)(19,721)
(Gain)/Loss from discontinued operations333431(342)
Net loss after discontinued operations$(25,019)$(5,467)$(30,115)$(19,379)
Other comprehensive loss:
Foreign exchange translation gain (loss)(16)254(11)184
Comprehensive loss$(25,035)$(5,213)$(30,126)$(19,195)
Net loss per share
(USD ‘000)
 For the six months ended June 30, 
Operating activities
Net loss$(30,115)$(19,379)
Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized gain on changes in fair value of biological assets(5,655)(19,682)
Realized gain on changes in fair value of biological assets9,32012,515
Share-based compensation3,5173,249
Depreciation and amortization4,6754,059
Discontinued operations31(342)
Accretion of convertible debentures2,2423,834
Interest on lease liabilities1,2571,987
Change in fair market value of derivative(1,551)1,007
Loss on investment in associate215
Loss on debt restructuring8,065
Loss on debt settlement10,751
(Gain)/Loss on disposal of assets50(54)
Deferred tax expense9591,862
Changes in operating assets and liabilities:
Accounts receivable2611
Biological assets(4,246)5,265
Prepaid expenses and other current assets1,875(646)
Right-of-use assets(1,280)(728)
Right-of-use liabilties1,262
Other assets(61)(84)
Accounts payable(278)968
Accrued liabilities(651)1,083
Income taxes (10,523)4,410
Other liabilities115
Net cash provided by (used in) operating activities(18,949)2,329
Investing activities
Purchases of property and equipment(8,408)(2,126)
Payment of notes receivable284150
Proceeds from sale of property and equipment24
Notes receivable(1,020)(696)
Proceeds from sale of subsidiary600
Net cash used in investing activities(9,120)(2,072)
Financing activities
Proceeds from issuance of shares and warrants23,7304,351
Proceeds from issuance of debt, net of loan issuance costs63,13362
Payment of lease obligations(2,154)(2,133)
Exercise of warrants1,365
Principal repayments of notes payable(35,382)(35)
Net cash provided by financing activities50,6922,245
Effect of foreign exchange on cash and cash equivalents(11)184
Net increase (decrease) in cash and cash equivalents22,6122,686
Cash and cash equivalents, beginning of period3,3922,516
Cash and cash equivalents, end of period$26,004$5,202
USD (‘000)
Three months ended
June 30,June 30,
Net loss$(25,019)$(5,467)$(19,552)
Interest expense4,7193,798921
Income taxes5943,308(2,714)
Depreciation and amortization2,4292,064365
EBITDA$        (17,277)$3,702$(20,979)
Three months ended
June 30,June 30,
Change in fair value of biological assets5,951(2,619)8,570
Change in fair market value of derivative(1,143)(828)(315)
Loss on debt settlement10,75110,751
Private placement issuance expense6,6406,640
Share-based compensation2852,362(2,077)
Discontinued operations3334(1)
Loss on disposal of assets1$(54)55
Other non-recurring expense/(income)(18)31(49)
Adjusted EBITDA$5,223$2,628$2,595

View original content to download multimedia:

SOURCE Cansortium Inc

No comments so far.

Be first to leave comment below.

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.